Sachin D. Patel, a promoter of Gujarat Themis Biosyn Limited , proposes to acquire up to 26,00,000 equity shares from Themis Medicare Limited. The inter-se transfer, scheduled to occur between June 30 and July 3, 2026, represents up to 2.38% of the total share capital of the company. The acquisition is exempt from making an open offer under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The proposed acquisition price is fixed at Rs. 400.45 per share. The 60-day volume weighted average market price of the shares preceding the notice date was Rs. 369.15. The acquirer has declared that the transaction price does not exceed the permissible limit of 25% over the determined price. The transfer is classified as an inter-se transfer among the promoter and promoter group.

Following the transaction, the shareholding pattern will see a shift in ownership between the promoter entities. Dr. Sachin Patel’s holding is set to increase to 26,00,010 shares, constituting 2.38% of the share capital. Conversely, the seller, Themis Medicare Limited, will see its stake reduce from 23.19% to 20.81%.

Transaction Details

The acquirer has confirmed compliance with all conditions specified under the relevant regulations and affirmed that both transferor and transferee have adhered to applicable disclosure requirements in Chapter V of the Takeover Regulations.

Gujarat Themis Biosyn Limited has expanded its international footprint by incorporating a step-down subsidiary, Themis Biosyn Private Limited, in Ireland on June 16, 2026. The newly formed entity operates within the pharmaceutical industry and holds a share capital of 100 Euro. This strategic move aims to bolster the company's presence in the European market.

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Themis Biosyn Private Limited is a wholly owned subsidiary of Themis Biosyn Ireland Private Limited, which holds 100% of the shareholding.

Details regarding the incorporation were submitted to the BSE Limited and the National Stock Exchange of India Limited. The company clarified that the transaction does not fall under related party transactions, and no specific governmental or regulatory approvals were required for this incorporation.

The following table outlines the key details of the newly incorporated subsidiary:

The Board of Directors of Gujarat Themis Biosyn approved the strategic expansion, with the intimation signed by Dinesh S. Patel, Chairman & Director. The company received the business registration extract for the new entity on the same date as its incorporation.